Folate Receptor Alpha—A Novel Approach to Cancer Therapy
International Journal of Molecular Sciences · 15.01.2024 · 25 (2) · 1046
DOI: 10.3390/ijms25021046 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.01.2024. Verfasst von Teresita Gonzalez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Cancer Institute, Pembroke Pines, FL 33028, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 137-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Folate receptor α (FR) was discovered many decades ago, along with drugs that target intracellular folate metabolism, such as pemetrexed and methotrexate. Folate is taken up by the cell via this receptor, which also targeted by many cancer agents due to the over-expression of the receptor by cancer cells. FR is a membrane-bound glycosyl-phosphatidylinositol (GPI) anchor glycoprotein encoded by the folate receptor 1 (FOLR1) gene. FR plays a significant role in DNA synthesis, cell proliferation, DNA repair, and intracellular signaling, all of which are essential for tumorigenesis. FR is more prevalent in cancer cells compared to normal tissues, which makes it an excellent target for oncologic therapeutics. FRα is found in many cancer types, including ovarian cancer, non-small-cell lung cancer (NSCLC), and colon cancer. FR is widely used in antibody drug conjugates, small-molecule-drug conjugates, and chimeric antigen-receptor T cells. Current oncolytic therapeutics include mirvetuximab soravtansine, and ongoing clinical trials are underway to investigate chimeric antigen receptor T cells (CAR-T cells) and vaccines. Additionally, FRα has been used in a myriad of other applications, including as a tool in the identification of tumor types, and as a prognostic marker, as a surrogate of chemotherapy resistance. As such, FRα identification has become an essential part of precision medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Memorial Cancer Institute, Pembroke Pines, FL 33028, USA.
ORCID-Profile: Meri Muminovic
Zitieren
APA
Gonzalez, T., Muminovic, M., Nano, O., & Vulfovich, M. (2024). Folate Receptor Alpha—A Novel Approach to Cancer Therapy. International Journal of Molecular Sciences, 25(2), 1046. https://doi.org/10.3390/ijms25021046
Vancouver
Gonzalez T, Muminovic M, Nano O, Vulfovich M. Folate Receptor Alpha—A Novel Approach to Cancer Therapy. International Journal of Molecular Sciences. 2024;25(2):1046. doi:10.3390/ijms25021046
BibTeX
@article{Gonzalez2024,
author = {Gonzalez, Teresita and Muminovic, Meri and Nano, Olger and Vulfovich, Michel},
title = {Folate Receptor Alpha—A Novel Approach to Cancer Therapy},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {2},
pages = {1046},
doi = {10.3390/ijms25021046}
}
EUVIMED